Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen

Urology

Volumn 55, Issue 4, 2000, Pages 481-485

  Recker, Franz ^d   Kwiatkowski, MacIej K ^a   Piironen, Timo ^b   Pettersson, Kim ^b   Huber, Andreas ^a   Lümmen, Gerd ^c   Tscholl, Reto ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN;

ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS;

EID: 0034064641     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00611-1     Document Type: Article

References (17)

1. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., et al. Human kallikrein 2 (hK2) and prostate specific antigen (PSA) two closely related but distinct, kallikreins in the prostate . Crit Rev Clin Lab Sci. 35:1998;275-368.
2. Lovgren J., Rajakoski K., Karp M., et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun. 238:1997;549-555.
3. Recker F., Kwiatkowski M.K., Pettersson K. Correlation of human glandular kallikrein (hK2) with free and total prostatic specific antigen (PSA) and alpha 1 antichymotrypsin in different prostatic diseases. Akt Urol. 29:1998;44.
4. Kwiatkowski M.K., Recker F., Piironen T., et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology. 52:1998;360-365.
5. Recker F., Kwiatkowski M.K., Piironen T. Improving the specificity of PSA's in the diagnostic gray zone 4-10 ng/ml by human glandular kallikrein. Urologe A. 37:1998;421-423.
6. Recker F., Kwiatkowski M.K., Piironen T., et al. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer. 83:1998;2540-2547.
7. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
8. Brawer M.K., Chetner M.P., Beatie J., et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 147:1992;841-845.
9. Dillioglugil Ö., Miles B.J., Scardino P.T. Current controversies in the management of localised prostate cancer. Eur Urol. 28:1995;85-101.
10. Partin A.W., Carter H.B., Chan D.W., et al. Prostate specific antigen in the staging of localized prostate cancer influence of tumor differentiation, tumor volume and benign hyperplasia . J Urol. 143:1990;747-752.
11. Recker F., Kwiatkowski M.K., Pettersson K., et al. Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia. Eur Urol. 33:1998;549-555.
12. Piironen T., Lovgren J., Karp M., et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem. 42:1996;1034-1041.
13. 1-antichymotrypsin complex . Clin Chem. 41:1995;1480-1488.
14. Chodak G.W., Thisted R.A., Gerber G.S., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 330:1994;242-248.
15. Pannek J., Partin A.W. Prostate-specific antigen what's new in 1997 . Oncology. 11:(Huntingt):1997;1273-1278.
16. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma a novel prostate cancer marker . Urology. 49:1997;857-862.
17. Partin A.W., Kattan M.W., Subong E.N.J.E., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1997;1445-1451.